Across TCGA pan-cancer cohorts, DLX1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DLX1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher DLX1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DLX1 expression acts as an unfavorable survival marker.
SCLC, SKCM, and ACC are the cancer types where DLX1 Mutation most reproducibly stratifies survival.